pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Aristada
drug
save

aripiprazole lauroxil ER

Marketedupdated 2mo ago
by Alkermes US Holdings Inc
Approved
community read0 votes

indications

investigational
Schizophrenia

all catalysts(0)

nothing on the calendar yet

Trials studying aripiprazole lauroxil ER

  • phase4C-Cog in Early Course Schizophrenia Studyterminatedn=1
  • phase4Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episodeterminatedn=15

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 24, 2030
~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (71)

  • Apr 6, 2039method-of-use (U-543)US 11273158
  • Apr 6, 2039method-of-use (U-543)US 11273158
  • Apr 6, 2039method-of-use (U-543)US 11273158
  • Apr 6, 2039method-of-use (U-543)US 11273158
  • Apr 6, 2039method-of-use (U-543)US 11273158
  • Apr 6, 2039method-of-use (U-543)US 12251381
  • Apr 6, 2039method-of-use (U-543)US 12251381
  • Apr 6, 2039method-of-use (U-543)US 12251381
  • Apr 6, 2039method-of-use (U-543)US 12251381
  • Apr 6, 2039method-of-use (U-543)US 12251381
  • Sep 8, 2035formulationUS 10016415
  • Aug 17, 2035formulationUS 10688091
  • Aug 17, 2035method-of-use (U-543)US 10849894
  • Aug 17, 2035formulationUS 11154552
  • Mar 19, 2035method-of-use (U-2402)US 10238651
  • Mar 19, 2035method-of-use (U-2402)US 10238651
  • Mar 19, 2035method-of-use (U-2402)US 10238651
  • Mar 19, 2035method-of-use (U-2402)US 10238651
  • Mar 19, 2035method-of-use (U-2402)US 10813928
  • Mar 19, 2035method-of-use (U-2983)US 10813928
  • Mar 19, 2035method-of-use (U-2983)US 10813928
  • Mar 19, 2035method-of-use (U-2983)US 10813928
  • Mar 19, 2035method-of-use (U-2402)US 11406632
  • Mar 19, 2035method-of-use (U-2402)US 11406632
  • Mar 19, 2035method-of-use (U-2402)US 11406632
  • Mar 19, 2035method-of-use (U-2402)US 11406632
  • Mar 19, 2035method-of-use (U-2402)US 9452131
  • Mar 19, 2035method-of-use (U-2402)US 9452131
  • Mar 19, 2035method-of-use (U-2402)US 9452131
  • Mar 19, 2035method-of-use (U-2402)US 9452131
  • Mar 19, 2035formulationUS 9526726
  • Mar 19, 2035formulationUS 9526726
  • Oct 24, 2033formulationUS 11097006
  • Oct 24, 2033formulationUS 11097006
  • Oct 24, 2033formulationUS 11097006
  • Oct 24, 2033formulationUS 11097006
  • Oct 24, 2033formulationUS 11969469
  • Oct 24, 2033formulationUS 11969469
  • Oct 24, 2033formulationUS 11969469
  • Oct 24, 2033formulationUS 11969469
  • Oct 24, 2033formulationUS 9193685
  • Oct 24, 2033formulationUS 9193685
  • Oct 24, 2033formulationUS 9193685
  • Oct 24, 2033formulationUS 9193685
  • Sep 19, 2033formulationUS 12311027
  • Sep 19, 2033formulationUS 12311027
  • Sep 19, 2033formulationUS 12311027
  • Sep 19, 2033formulationUS 12311027
  • Nov 7, 2032formulationUS 9034867
  • Nov 7, 2032formulationUS 9034867
  • Nov 7, 2032formulationUS 9034867
  • Nov 7, 2032formulationUS 9034867
  • Mar 19, 2032method-of-use (U-543)US 10226458
  • Mar 19, 2032method-of-use (U-543)US 10226458
  • Mar 19, 2032method-of-use (U-543)US 10226458
  • Mar 19, 2032method-of-use (U-543)US 10226458
  • Oct 26, 2030compositionUS 84315764.3y
  • Oct 26, 2030compositionUS 84315764.3y
  • Oct 26, 2030compositionUS 84315764.3y
  • Oct 26, 2030compositionUS 84315764.3y
  • Oct 26, 2030compositionUS 84315764.3y
  • Jun 24, 2030compositionUS 101129033.9y
  • Jun 24, 2030compositionUS 101129033.9y
  • Jun 24, 2030compositionUS 101129033.9y
  • Jun 24, 2030compositionUS 101129033.9y
  • Jun 24, 2030compositionUS 101129033.9y
  • Jun 24, 2030method-of-use (U-543)US 87962763.9y
  • Jun 24, 2030method-of-use (U-543)US 87962763.9y
  • Jun 24, 2030method-of-use (U-543)US 87962763.9y
  • Jun 24, 2030method-of-use (U-543)US 87962763.9y
  • Jun 24, 2030method-of-use (U-543)US 87962763.9y

News(0)

no news has mentioned this drug yet

brand
Aristada
generic
aripiprazole lauroxil
indication
Schizophrenia
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?